Loading provider…
Loading provider…
Hematology & Oncology Physician in Wesley Chapel, FL
NPI: 1043224819Primary Employer
Moffitt Medical Group
moffitt.org
HQ Phone
Get M.D. Alison's Phone Numberphone_androidMobile
Get M.D. Alison's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardOH State Medical License
FL State Medical License
FL State Medical License
2022 - 2026
OH State Medical License
2008 - 2023
NY State Medical License
2005 - 2008

American Board of Internal Medicine
Hematology
University of Rochester Medical Center
urmc.rochester.edu
Medical School
Until 2002
Fellowship • Hematology and Medical Oncology
2005 - 2008
Residency • Internal Medicine
2002 - 2005
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99205New patient office or other outpatient visit, typically 60 minutes | 51 | 51 |
| 2 | 99214Established patient office or other outpatient visit, 30-39 minutes | 48 | 72 |
| 3 | 99215Established patient office or other outpatient, visit typically 40 minutes | 44 | 92 |
| 4 | 99204New patient office or other outpatient visit, 45-59 minutes | 18 | 18 |
DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia
Novel therapies upon failure of HMA plus venetoclax.
Authors: Onyee Chan
Journal: Hematology Am Soc Hematol Educ Program
Authors: Richard Larson, Robert Stuart, John Byrd, Jonathan Kolitz, Richard Stone, Guido Marcucci, Jun Yin, Mohan Thakuri, William Blum, Grerk Sutamtewagul
Journal: Blood Adv
Lead Sponsor: Alison Walker
Intervention / Treatment: OTHER: laboratory biomarker analysis, OTHER: pharmacological study, DRUG: decitabine, DRUG: HDAC inhibitor AR-42
Lead Sponsor: National Cancer Institute (NCI)
Intervention / Treatment: OTHER: Laboratory Biomarker Analysis, OTHER: Pharmacological Study, DRUG: Decitabine, DRUG: Bortezomib, DRUG: Sorafenib Tosylate
Lead Sponsor: Alison Walker
Collaborators: Novartis, Millennium Pharmaceuticals, Inc.
Intervention / Treatment: DRUG: Bortezomib, DRUG: etoposide, DRUG: cytarabine, DRUG: midostaurin, DRUG: mitoxantrone hydrochloride